Rami Kremien

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.

Lipomedix Pharmaceuticals Ltd. engages in the development of cancer therapy based on liposome delivery. It offers Promitil®, a proprietary formulation of a lipid-based pro-drug of MMC (MLP) which enables efficient delivery and release of active MMC to tumors in vivo. The company was founded by Alberto Gabizon and Rami Kremien and is headquartered in Jerusalem, Israel.